The Medical Services Advisory Committee has responded to the health minister's assessment of its decision-making as "clunky" and causing deaths due to delays in funded access by deferring an outcome on the therapy that was the source of the critique.
MSAC doubles-down and defers outcome despite minister's criticism of delays and deaths
February 23, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New report shows precision approach extends lives but many still missing out
November 25, 2025 - - Latest News -
AusBiotech appoints Anthea Stephenson to lead national industry growth program
November 25, 2025 - - Australian Biotech -
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 - - Australian Biotech -
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News
